Skip to search formSkip to main contentSkip to account menu

ErbB-2 Inhibitor ARRY-380

Known as: ONT-380 
An orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

ARRY-380
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract P1-12-04: Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in patients (pts) with HER2+ breast cancer brain metastases
Background: Brain metastases remain an important cause of death for pts with advanced HER2+ BC. ONT-380 is an oral, potent and… 
2016
2016
Abstract P4-14-19: ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets)
Background: The risk of CNS involvement in patients with HER2+ metastatic breast cancer (MBC) is high. The natural history of… 
2016
2016
Abstract P4-14-20: A phase 1b study of ONT 380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+ metastatic breast cancer (MBC)
Background: ONT 380 is a potent HER2 selective tyrosine kinase inhibitor with minimal EGFR-like side effects. Preclinical studies… 
2016
2016
First Patient Dosed on ONT-380 HER2-Positive Breast Cancer Trial
The dual action of ONT-380, which is an oral, HER2-selective, central nervous system (CNS)-active tyrosine kinase inhibitor, may… 
2015
2015
ONT-380 Active Against CNS Mets in HER2-Positive Breast Cancer
Two studies of the new HER2 selective tyrosine kinase inhibitor ONT-380 showed the drug has promising activity in HER2-positive… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)